-
Je něco špatně v tomto záznamu ?
Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
[Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists]
M. Holická, J. Vysloužil, K. Kubová, J. Muselík, D. Vetchý
Jazyk čeština Země Česko
Typ dokumentu přehledy, práce podpořená grantem
- MeSH
- hormon uvolňující gonadotropiny * agonisté antagonisté a inhibitory aplikace a dávkování biosyntéza chemie farmakologie fyziologie klasifikace MeSH
- veterinární léky aplikace a dávkování klasifikace MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropin-releasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flare-up phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22022583
- 003
- CZ-PrNML
- 005
- 20221114141515.0
- 007
- ta
- 008
- 220929s2021 xr f 000 0|cze||
- 009
- AR
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Holická, Martina $7 xx0260799 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 245 10
- $a Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté / $c M. Holická, J. Vysloužil, K. Kubová, J. Muselík, D. Vetchý
- 246 31
- $a Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists
- 504 __
- $a Literatura
- 520 9_
- $a Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropin-releasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flare-up phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
- 650 17
- $a hormon uvolňující gonadotropiny $x agonisté $x antagonisté a inhibitory $x aplikace a dávkování $x biosyntéza $x chemie $x farmakologie $x fyziologie $x klasifikace $7 D007987 $2 czmesh
- 650 _7
- $a veterinární léky $x aplikace a dávkování $x klasifikace $7 D019155 $2 czmesh
- 655 _7
- $a přehledy $7 D016454 $2 czmesh
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 700 1_
- $a Vysloužil, Jakub $7 xx0231488 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 700 1_
- $a Kubová, Kateřina $7 xx0231489 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 700 1_
- $a Muselík, Jan $7 xx0100243 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 700 1_
- $a Vetchý, David, $d 1972- $7 mzk2006368163 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 773 0_
- $t Chemické listy $x 0009-2770 $g Roč. 115, č. 10 (2021), s. 516-523 $w MED00011010
- 856 41
- $u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844 $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 1918 $c 395 $y p $z 0
- 990 __
- $a 20220929104939 $b ABA008
- 991 __
- $a 20221114141512 $b ABA008
- 999 __
- $a ok $b bmc $g 1842929 $s 1173868
- BAS __
- $a 3
- BMC __
- $a 2021 $b 115 $c 10 $d 516-523 $i 0009-2770 $m Chemické listy $x MED00011010
- LZP __
- $c NLK189 $d 20221114 $a NLK 2022-17/kv